Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- New JPMA Chief Calls for Scrapping PMP Company Criteria
June 1, 2018
- Sawai President Elected New Generic Industry Chief
May 30, 2018
- Drug Damage Watchdog Submits Opinion to Health Ministry, Opposing Current Conditional Early Approval System
May 30, 2018
- Big Data Analysis Finds Low Generic Drug Use Rate among Healthcare Professionals: Kyokai Kenpo
May 28, 2018
- Daiichi Sankyo CEO Nakayama Appointed as New President of JPMA
May 25, 2018
- Isao Teshirogi Elected New FPMAJ Chairman
May 25, 2018
- PhRMA Vision Report Stresses Innovation as Investment for Healthier Lifespans
May 17, 2018
- Over 80% Concerned about Restrictions on Access to Prescription Drugs: PhRMA Survey
May 15, 2018
- Drug Damage Watchdog Calls for 3rd Party Long-Term Investigation for HPV
May 2, 2018
- PhRMA/EFPIA Deeply Concerned about MOF Pitch on Stringent CEA Application
April 26, 2018
- PhRMA/EFPIA Say Humira, Jevtana, Xarelto Lost Eligibility under New PMP, Innovation Not Appropriately Defined
April 26, 2018
- No Dialogue at New “Public-Private Dialogue” Confab with Limited Time, JPMA Says
April 20, 2018
- Asian Industry Groups Agree to Use Common Site Master File for Plant Inspections
April 16, 2018
- PhRMA Chief Warns of Serious Implications for Japan Market after 2018 Pricing Reform
April 13, 2018
- Company Category Criteria for Price Maintenance Premium Tough on Ophthalmic Drug Makers: Industry Group
April 9, 2018
- Japan CRO Association Members Deliver Actual 8.1% Sales Surge in 2017
April 5, 2018
- GHIT Fund to Make New Investment of 1.66 Billion Yen for Development of Therapies and Vaccines
March 30, 2018
- 100 Infusion Products Got Price Raises under Unprofitability Re-Pricing, but Drastic Pricing Reform Still Necessary: IV Solution Society
March 26, 2018
- Americas Chief James Robinson Leaves Astellas, What Will Happen to PhRMA Treasurer Seat?
March 20, 2018
- Annual Re-Pricing Key Focus Issue for Japan Pharma Trade Group in FY2018
March 16, 2018
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…